E. Sasso
Rheumatology · 2008
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Rheumatology — 28 citations into it
Whom E. Sasso trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from E. Sasso's perspective
Ordered by how strongly the researchers E. Sasso trusts endorse each paper. Same corpus, a different order for every researcher.
- Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (New England Journal of Medicine)
- A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. (New England Journal of Medicine)
- Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? (Annual Review of Immunology)
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. (The Lancet)
- The British Society for Rheumatology Biologics Register (Annals of the Rheumatic Diseases)
- NF-κB functions as a tumour promoter in inflammation-associated cancer (Nature)
- Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. (Arthritis & Rheumatism)
- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. (Gastroenterology)
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving… (Arthritis & Rheumatism)
- Cytokine pathways and joint inflammation in rheumatoid arthritis. (New England Journal of Medicine)
Their papers
- Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008) — 1,692 citations